A real-world study of the safety and efficacy of Ganmaoling granules (999) in the treatment of the common cold

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029753

Enrollment

Unknown

Registered

2020-02-12

Start date

2020-02-10

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common cold

Interventions

Group A:ganmaoling

Group B:Western medicine compound preparation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed as common cold; 2. Aged >=18 years old; 3. This prescription contains Ganmaoling granules (999) or any of the following western medicine compound preparations: meipu pseudotablet, compound aminophenol pseudotablet sustained release capsule, pseudoaminophenol pseudoamefen tablet, aminophenemide tablet, compound aminophenolamine tablet (capsule), phenolcahuang capsule; 4. Participate in this study voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Failure to cooperate to complete information collection; 2. The researcher considers it inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
effective rate;symptom score;Complication rate;Drug combination;AE;ADR;	—

Countries

China

Contacts

Public ContactZhang Hongchun

Beijing Qihuang Medicine Clinical Research Center

13701226664@139.com+86 13701226664

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026